CHClaudia Beatriz Hereñú

Claudia Beatriz Hereñú

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Claudia Beatriz Hereñú has a total of 74 co-authors. Here are the top co-authors by number of shared publications:

  • María José Bellini

    Instituto de Investigaciones Bioquímicas de La Plata (INIBIOLP-CONICET), La Plata, Argentina, Argentina

    9 shared publications
  • Macarena Lorena Herrera

    Universidad Nacional de Córdoba, Facultad de Ciencias Químicas, Departamento de Farmacología, Instituto de Farmacología Experimental de Córdoba (IFEC-CONICET), Córdoba, Argentina; Instituto de Investigaciones Bioquímicas de La Plata, Facultad de Ciencias Médicas, Universidad Nacional de La Plata (INIBIOLP-CONICET-UNLP), Buenos Aires, Argentina

    8 shared publications
  • Leandro Gabriel Champarini

    IFEC-CONICET, Departamento de Farmacología Otto Orsingher, Facultad de Ciencias Químicas, Universidad Nacional de Córdoba, Haya de la Torre y Medina Allende, Ciudad Universitaria

    5 shared publications
  • Leandro Gabriel Champarini

    IFEC‐CONICET, Departamento de Farmacología Otto Orsingher, Facultad de Ciencias Químicas Universidad Nacional de Córdoba Córdoba Argentina

    4 shared publications
  • Eugenia Falomir-Lockhart

    Laboratorio de Bioquímica del Envejecimiento, Instituto de Investigaciones Bioquímicas de La Plata (INIBIOLP), Facultad de Ciencias Médicas, UNLP-CONICET, Buenos Aires, Argentina

    3 shared publications
  • Franco Juan Cruz Dolcetti

    Laboratorio de Bioquímica del Envejecimiento, Instituto de Investigaciones Bioquímicas de La Plata (INIBIOLP), Facultad de Ciencias Médicas, UNLP-CONICET, Buenos Aires, Argentina

    3 shared publications

Latest Publications

  • Open Access

    Intracisternal IGF-1 gene delivery attenuates early anxiety-like behavior but not dopaminergic neurodegeneration in a 6-OHDA rat model of parkinsonism

    by Leandro Gabriel Champarini, Macarena Lorena Herrera, Matías Jávega Cometto, Rocío del Valle Bartolozzi, Aracely Janneth Naranjo Viteri, Rosana Crespo, Gastón Diego Calfa, Claudia Beatriz Hereñú

    Background: Parkinson’s disease (PD) is a neurodegenerative disorder characterized by the progressive loss of dopaminergic neurons, leading to a spectrum of motor and non-motor symptoms. In addition to the motor deficits serving as the primary criteria for diagnosis, mood and anxiety disorders also play a significant role in shaping the prognosis and overall disease progression in PD. Objectives: In this study, our aim was to characterize the progression of anxiety-like behavioral deficits in a rat model of neurotoxicity induced by 6-hydroxydopamine (6-OHDA) and to investigate insulin-like growth factor 1 (IGF-1) potential therapeutic effects on these pathological markers. Methods: Behavioral changes were evaluated in male Wistar rats at 1, 2, and 3 weeks post-lesion using the elevated plus maze and dark–light box tests. Anxiety-like behaviors emerged as early as week 1 post-lesion and persisted through week 3. Following 6-OHDA infusion, immunohistochemical analysis revealed a decrease in tyrosine hydroxylase (TH) immunoreactivity within the ventral tegmental area (VTA) indicating a partial lesion of the nigrostriatal dopaminergic system. As a therapeutic approach we performed the intracisternal administration of a recombinant adenoviral vector encoding IGF-1 (RAd IGF-1) one week after 6-OHDA-induced neurotoxicity. Results: At a behavioral level, IGF-1 treatment effectively prevented anxiety-like behavior by the third week of neurotoxicity. Nevertheless, IGF-1 overexpression was not able to modulate VTA dopaminergic neuron loss. These results reveal a dissociation between the behavioral effects of IGF-1 and its impact on dopaminergic neurodegeneration. Discussion: These findings emphasize time-dependent alterations in anxiety-like behavior and dopaminergic neurodegeneration. In addition, these data support the potential use of IGF-1 as a therapeutic molecule and its novel administrations for future gene transfer interventions, which will shed light on the progressive nature of neurodegenerative mechanisms.

  • Trophic factors and essential oils as potential neuromodulators of Renin-Angiotensin system

    by Rosana Crespo, Sol Angulo, Lucía Nigro, Rocío Bartolozzi, Claudia Hereñú


  • Open Access

    Plant-Derived Monoterpene Therapies in Parkinson’s Disease Models: Systematic Review and Meta-Analysis

    by Matías Jávega-Cometto, Aracely J. Naranjo-Viteri, Leandro G. Champarini, Claudia B. Hereñú, Rosana Crespo

    Monoterpenes (MTs) are plants’ secondary metabolites and major components of essential oils (EOs), widely used in the pharmaceutical industry. However, its neuroprotective effects, particularly in Parkinson’s disease (PD) have not been fully demonstrated. PD is a progressive neurological disorder marked by dopaminergic neuron loss in the substantia nigra, motor symptoms being the most reported ones. This review evaluates the evidence supporting the use of MTs as potential neuroprotective agents. PubMed, SCOPUS, Google Scholar, and ScienceDirect databases were searched for articles on MTs in murine models with any type of administration. The PRISMA guidelines were followed. After screening 405 records, 32 were included in the systematic review and 30 were included in the meta-analysis. Fifteen MTs, commonly found in EOs, were identified as potential therapeutic agents for PD. The meta-analysis revealed that MTs administration improved motor performance, increased tyrosine hydroxylase levels, reduced oxidative stress markers (malondialdehyde) and proinflammatory cytokines (IL-6, IL-1, TNF-α), and enhanced antioxidant enzymes (catalase, superoxide dismutase) in parkinsonian animals. The antioxidant and anti-inflammatory properties of MTs appear to be key mechanisms in mitigating dopaminergic neurodegeneration. However, further clinical research is essential to translate these findings into practical applications.


  • Open Access

    Neurodegenerative processes of aging: A perspective of restoration through insulin-like growth factor-1

    by Rosana Crespo, Claudia Hereñú

    An abstract is unavailable. This article is available as a PDF only.

  • Open Access

    Potentialities of IGF-1 for regulating oxidative stress in neuroinflammation and neurodegeneration: theoretical review

    by Macarena Lorena Herrera, Leandro Gabriel Champarini, Alberto Leandro Oliveros, Maria José Bellini, Claudia Beatriz Hereñú

    Insulin-like growth factor-1 (IGF-1) elicits a variety of effects on the regulation of oxidative stress, a topic that remains shrouded in controversy. This intricate regulation plays a pivotal role in the aging process and its associated diseases. Notably, it centers around the challenge posed by endogenous antioxidant defenses, which often struggle to counteract free radicals-induced damage to various neural cell macromolecules. The interplay between IGF-1 and oxidative stress holds significant implications. Both factors are intertwined in the context of degenerative and inflammatory disruptions within the central nervous system (CNS), giving rise to dysfunctions in neurons and glial cells. These dysfunctions encompass detrimental outcomes such as excitotoxicity, neuronal attrition, and axonal impairment, all of which are closely related to behavioral irregularities. However, the complexities of IGF-1’s impact remain a topic of debate. Divergent research findings present IGF-1 as both an antioxidative agent and a catalyst to produce reactive oxygen species (ROS) in various neuropathologies. This diversity of outcomes has contributed to the ongoing controversy in the field. The present theoretical review undertakes a comprehensive vision, shedding light on the role of IGF-1 as a regulator within the mechanistic framework of oxidative stress responses. This regulatory role serves as the basis for the emergence of progressive neurodegenerative and neuroinflammatory conditions. Particularly compelling is the exploration of IGF-1 as a potential target for promising therapeutic interventions in this domain. However, the review also highlights significant limitations, including the considerations to work with this factor and the need for further research to clarify IGF-1’s role. Future perspectives should focus on refining our understanding of IGF-1’s mechanisms and exploring its therapeutic potential in more detail.


  • IGF-1 gene therapy prevents spatial memory deficits and modulates dopaminergic neurodegeneration and inflammation in a parkinsonism model

    by Macarena Lorena Herrera, Leandro Gabriel Champarini, Osvaldo Martín Basmadjian, María José Bellini, Claudia Beatriz Hereñú


  • Open Access

    IGF-1 GENE THERAPY ON GLIA CELLS AND DOPAMINERGIC NEURONS INTERACTION IN NEURODEGENERATIVE MODELS

    by Macarena Herrera, Leandro Champarini, Osvaldo Basmadjian, María José Bellini, Claudia Hereñú

  • Open Access

    NON-MOTOR SYMPTOMS IN A RAT MODEL OF NEUROTOXICITY INDUCED BY 6-OHDA: EFFECT OF INTRACISTERNAL RAD-IGF1 IN ANXIETY-LIKE BEHAVIOR

    by Leandro Champarini, Macarena Herrera, Matías Jávega, Aracely Naranjo Viteri, Rosana Crespo, Gastón Calfa, Claudia Hereñú

  • Effect of intra‐BLA overexpression of IGF‐1 on the expression of a contextual fear memory trace

    by Leandro Gabriel Champarini, Macarena Lorena Herrera, Ramiro Gabriel Comas Mutis, Pablo Javier Espejo, Victor Alejandro Molina, Gastón Diego Calfa, Claudia Beatriz Hereñú

    Growth factors, such as insulin‐like growth factor 1 (IGF‐1), among others are known for their critical involvement in learning and memory processes. IGF‐1 regulates cognitive functions, synapse density, neurotransmission, and adult neurogenesis and induces structural and synaptic plasticity‐specific changes. Although IGF‐1 has been suggested to participate in different memory processes, its role in memories associated with negative emotional experiences still remains to be elucidated. The principal aim of the present study was to test whether IGF‐1 overexpression using adenoviral vectors in basolateral amygdala (BLA) influences both the expression and formation of contextual fear memory, as well as the hippocampal structural plasticity associated with such memory trace. We found that IGF‐1 overexpression promotes the formation and expression of a specific contextual fear memory trace, and such effect persisted at least 7 days after recall. Moreover, the overexpression of this growth factor in BLA upregulates the activation of the ERK/MAPK pathway in this brain structure. In addition, intra‐BLA IGF‐1 overexpression causes dorsal hippocampus (DH) structural plasticity modifications promoting changes in the proportion of mature dendritic spines in the CA1 region, after a weak conditioning protocol. The present findings contribute to the knowledge underlying BLA‐DH trace memory of fear and reveal important new insights into the neurobiology and neurochemistry of fear acquisition modulated by IGF‐1 overexpression. The understanding of how IGF‐1 modulates the formation of a fear contextual trace may pave the way for the development of novel therapeutic strategies focused on fear, anxiety, and trauma‐related disorders.


  • IGF-1 Gene Transfer Modifies Inflammatory Environment and Gene Expression in the Caudate-Putamen of Aged Female Rat Brain

    by Eugenia Falomir-Lockhart, Franco Juan Cruz Dolcetti, Macarena Lorena Herrera, Jerónimo Pennini, María Florencia Zappa Villar, Gabriela Salinas, Enrique Portiansky, Björn Spittau, Ezequiel Lacunza, Claudia Beatriz Hereñú, et al.

    Brain aging is characterized by chronic neuroinflammation caused by activation of glial cells, mainly microglia, leading to alterations in homeostasis of the central nervous system. Microglial cells are constantly surveying their environment to detect and respond to diverse signals. During aging, microglia undergoes a process of senescence, characterized by loss of ramifications, spheroid formation, and fragmented processes, among other abnormalities. Therefore, the study of changes in microglia during is of great relevance to understand age‐related declines in cognitive and motor function. We have targeted the deleterious effects of aging by implementing IGF-1 gene transfer, employing recombinant adenoviral vectors (RAds) as a delivery system. In this study, we performed intracerebroventricular (ICV) RAd-IGF-1 or control injection on aged female rats and evaluated its effect on caudate-putamen unit (CPu) gene expression and inflammatory state. Our results demonstrate that IGF-1 overexpression modified aged microglia of the CPu towards an anti-inflammatory condition increasing the proportion of double immuno-positive Iba1+Arg1+ cells. We also observed that phosphorylation of Akt was increased in animals treated with RAd-IGF-1. Moreover, IGF-1 gene transfer was able to regulate CPu pro-inflammatory environment in female aged rats by down-regulating the expression of genes typically overexpressed during aging. RNA-Seq data analysis identified 97 down-modulated DEG in the IGF-1 group as compared to the DsRed one. Interestingly, 12 of these DEG are commonly overexpressed during aging, and 9 out of 12 are expressed in microglia/macrophages and are involved in different processes that lead to neuroinflammation and/or neuronal loss. Finally, we observed that IGF-1 overexpression led to an improvement in motor functions. Although further studies are necessary, with the present results, we conclude that IGF-1 gene transfer is modifying both the pro-inflammatory environment and activation of microglia/macrophages in CPu. In this regard, IGF-1 gene transfer could counteract the neuroinflammatory effects associated with aging and improve motor functions in senile animals. Graphical abstract